Novartis AG (NVS)

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

19 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Ken Fisher, Fisher Asset Management, LLC$2.43B · 0.7% of book
• Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$123.50M · 0.2% of book
• Dodge & Cox, DODGE & COX$119.01M · 0.1% of book
• Israel Englander, MILLENNIUM MANAGEMENT LLC$118.80M · 0.0% of book
• Farallon Capital, FARALLON CAPITAL MANAGEMENT, L.L.C.$56.89M · 0.3% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in NVS

We hold 32 disclosed trades in NVS by members of Congress and executive-branch officials. The latest 5:

• Kevin Hern · HouseSell · $15,001 - $50,000 · traded 27 Aug 2026 · disclosed 25 Sept 2026
• Alan Armstrong · SenateBuy · $1,001 - $15,000 · traded 31 Mar 2026 · disclosed 21 Jul 2026
• Alan Armstrong · SenateBuy · $15,001 - $50,000 · traded 30 Mar 2026 · disclosed 21 Jul 2026
• George Whitesides · HouseSell · $100,001 - $250,000 · traded 24 Mar 2025 · disclosed 23 Apr 2025
• Daniel Goldman · HouseSell · $50,001 - $100,000 · traded 10 Jul 2023 · disclosed 13 Aug 2023

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions